We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status
Aprocitentan Dual endothelin receptor antagonist Resistant hypertension management Advancing to Phase 3
ACT-541468 Dual orexin receptor antagonist Insomnia Advancing to Phase 3
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Advancing to Phase 3
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2
Vamorolone*** Dissociative steroid Duchenne muscular dystrophy Phase 2
ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome (ACS) Phase 2
ACT-774312 CRTH2 receptor antagonist Asthma and allergy disorders Phase 1
ACT-519276 GBA2/GCS inhibitor Orphan CNS diseases Phase 1
ACT-539313 Selective orexin 1 receptor antagonist Anxiety Phase 1
ACT-709478 T-type calcium channel blocker Epilepsy Phase 1


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** In Japan, market registration trials are being conducted, with results expected in the second half of 2018
*** Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone.